Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab/Tiragolumab - Roche

Next Previous
Drug Profile

Atezolizumab/Tiragolumab - Roche

Alternative Names: Atezolizumab/Tiragolumab; MPDL 3280A/MTIG 7192A; RG 7446/RG 6058; RG7446 42/RG6058 11; RO 5541267/RO 7092284

Latest Information Update: 22 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 26 Dec 2025 Roche completes a phase-II SKYSCRAPER-11 clinical trials in Solid tumours (Late-stage disease, Recurrent, Metastatic disease) in Turkey, Taiwan, Spain, South Korea, Serbia, Greece, Croatia, China, USA (IV) (NCT05661578)
  • 22 Dec 2022 Preclinical trials in Solid tumours in Switzerland (IV) (NCT05661578)
  • 22 Dec 2022 Roche plans phase II SKYSCRAPER-11 trial (Late-stage disease, Recurrent and Metastatic disease) in Solid tumours (IV) (NCT05661578) (EudraCT Number-2022-001157-23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top